Luis García‐Ortiz

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study

Rafel Ramos, Marc Comas‐Cufí, Ruth Martí‐Lluch et al. · BMJ · 2018 · 226 citations · Full text

Medicine, Geriatric Medicine, Pharmacotherapy +17

Abdominal obesity vs general obesity for identifying arterial stiffness, subclinical atherosclerosis and wave reflection in healthy, diabetics and hypertensive

José I. Recio-Rodríguez, Manuel A. Gómez‐Marcos, María C. Patino‐Alonso et al. · BMC Cardiovascular Disorders · 2012 · 142 citations · Full text

Veterinary Medicine, Cardiology, Diabetology +15

Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients

Ana M. Blázquez‐Medela, Luis García‐Ortiz, Manuel A. Gómez‐Marcos et al. · BMC Medicine · 2010 · 120 citations · Full text

Medicine, Endocrinology, Internal Medicine +17